JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Methods and Tools for Toxicity Assessment of Herbal Remedies

Neeta Rai[1*], Amrita Thakur[1], Vaishnavi Shreepati[2], Siddharth Chavan[2]

[1] *Assistant Professor, School of Pharmacy, Vishwakarma University, Pune, Maharashtra, India*
[2] *UG Scholar, School of Pharmacy, Vishwakarma University, Pune, Maharashtra, India*

Publication history: Received on 2nd June; Revised on 15th June; Accepted on 2nd July 2024

Article DOI: 10.69613/2w9xeg16

Abstract: Herbal remedies, used for millennia, require rigorous safety, efficacy, and quality evaluations due to their widespread use. Assessing the toxicity of herbal remedies involves multifaceted approaches including in vitro and in vivo methodologies, clinical trials, and regulatory frameworks. Acute, sub-acute, and chronic toxicity testing paradigms are crucial for establishing dose-response relationships and identifying potential risks. The complexity of toxicity assessment in herbal products stems from their multi-component nature and potential interactions. Advanced analytical techniques such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy play a vital role in identifying and quantifying potentially toxic compounds. Pharmacovigilance is essential for monitoring adverse reactions and ensuring long-term safety. The regulatory landscape surrounding herbal medicines varies globally, highlighting the need for harmonized standards. Emerging technologies like -omics approaches and in silico modelling promise to revolutionize toxicity assessments. Current knowledge synthesis reveals critical gaps in herbal remedy toxicity assessment methods. These tools and methodologies are crucial for safeguarding public health and integrating herbal medicine into modern healthcare systems, emphasizing the importance of continued research and development in this field.

Keywords: Herbal toxicity assessment; *In vitro* and *in vivo* testing; Pharmacovigilance; Safety profile; Phytomedicine.

1. Introduction

Herbal remedies have been an integral part of traditional medicine systems for thousands of years, offering a diverse array of therapeutic options for various ailments. The global resurgence of interest in natural and alternative medicine has led to a significant increase in the use of herbal products in recent decades [1]. This trend is driven by factors such as the perceived safety of natural products, dissatisfaction with conventional medicine, and the desire for more holistic approaches to health [2]. Despite their long history of use, the safety of herbal remedies cannot be assumed without rigorous scientific evaluation. The complex nature of herbal products, containing multiple active compounds, poses unique challenges in assessing their potential toxicity and interactions [3]. Unlike conventional pharmaceuticals, which typically contain a single active ingredient, herbal preparations may have hundreds of constituents, making it difficult to isolate and study individual components [4].

The misconception that "natural" equates to "safe" has led to a concerning trend of self-medication with herbal products, often without proper medical supervision or consideration of potential risks [5]. This situation is further complicated by the variable quality of herbal products available in the market, inconsistent regulatory standards across different countries, and the potential for adulteration or contamination [6]. Reports of adverse effects associated with herbal remedies have been increasing, ranging from mild gastrointestinal disturbances to severe hepatotoxicity, nephrotoxicity, and even fatalities [7]. These cases underscore the critical need for comprehensive toxicity assessments of herbal products to ensure public safety and maintain consumer confidence in natural therapies. Toxicity testing of herbal remedies encompasses a wide range of methodologies, from in vitro cellular assays to in vivo animal studies and human clinical trials [8]. Acute toxicity studies, typically conducted in animal models, aim to determine the lethal dose (LD50) and identify immediate adverse effects of single or multiple doses within a 24-hour period [9]. Sub-acute and chronic toxicity studies, on the other hand, investigate the effects of repeated exposure over extended periods, providing crucial information on potential cumulative toxicity and organ-specific damage [10]. The importance of toxicity testing extends beyond merely identifying harmful effects. It plays a pivotal role in establishing safe dosage ranges, understanding dose-response relationships, and elucidating mechanisms of toxicity [11]. This information is essential for developing evidence-based guidelines for the use of herbal products and informing regulatory decisions. Advanced analytical techniques have revolutionized the field of herbal toxicology. High-performance liquid chromatography (HPLC), coupled with mass spectrometry (MS), allows for the precise identification and quantification of potentially toxic compounds in complex herbal matrices [12]. Nuclear magnetic resonance (NMR) spectroscopy provides detailed structural information on herbal constituents, aiding in the characterization of novel toxic compounds [13]. These

* Corresponding author: Neeta Rai et al

technologies, combined with emerging -omics approaches such as toxicogenomics and metabolomics, offer unprecedented insights into the molecular mechanisms of herbal toxicity [14]. Pharmacovigilance plays a crucial role in monitoring the safety of herbal products post-market. Systematic collection and analysis of adverse event reports can identify rare or long-term toxicities that may not be apparent in pre-clinical or clinical studies [15]. However, the effectiveness of pharmacovigilance for herbal products is often hampered by underreporting and the challenges of establishing causality in complex herbal formulations [16]. The regulatory landscape for herbal medicines varies significantly across the globe, presenting challenges for standardization and quality control. In some countries, herbal products are regulated as dietary supplements with minimal pre-market safety evaluations, while others have stringent pharmaceutical-like regulations [17]. This disparity in regulatory approaches highlights the need for harmonized international standards and guidelines for herbal product safety assessment.

2. Toxicity Testing

Toxicity testing is a critical component in evaluating the safety profile of herbal remedies before their use in humans. These tests are designed to identify potential risks associated with the consumption of herbal products and to establish safe dosage ranges [20]. The use of animal models in toxicity testing provides several advantages, including the ability to control genetic factors, exposure duration, and the opportunity for comprehensive tissue examination post-mortem [21].

2.1. Importance of Toxicity Testing

Toxicity testing serves multiple crucial purposes in the development and regulation of herbal remedies:

2.1.1. Preparation of Dose-response curves

Toxicity tests allow researchers to establish the relationship between the dose of an herbal preparation and its biological effects. This information is crucial for determining therapeutic windows and potential toxic thresholds [22].

2.1.2. Assessing safety and efficacy

By systematically evaluating the effects of herbal remedies at various doses and durations, toxicity testing provides vital data on both the safety profile and potential therapeutic efficacy of these products [23].

2.1.3. Validation of new testing methods

Toxicity testing also plays a role in validating novel research methodologies, particularly in vitro techniques that aim to reduce animal testing. These new methods must be rigorously compared to established in vivo models to ensure their reliability and predictive power [24]

2.2. Types of Toxicity

Toxicity testing for herbal remedies typically encompasses three main categories: acute, sub-acute, and chronic toxicity studies (Figure 1). Each type of study provides unique insights into the safety profile of herbal products



Figure 1. Types Of Toxicity

2.2.1. Acute toxicity studies:

Acute toxicity studies focus on the adverse effects that occur following a single exposure or multiple exposures within a short timeframe, typically 24 hours for oral or dermal administration, and 4 hours for inhalation [25].

Testing: Acute toxicity tests are fundamental in chemical risk assessments for both environmental species and humans. The primary metric derived from these studies is the LD50 (Lethal Dose 50%), which represents the dose at which 50% of the test animals die [26]. This value serves as a crucial indicator of a substance's acute toxicity potential.

Animal Model: Rats are commonly used for acute toxicity studies due to their cost-effectiveness, availability, and ease of handling. Their physiological similarities to humans also make them suitable models for extrapolating potential human toxicity [27].

Methodology: Typically, groups of animals are administered single doses of the herbal preparation at different concentrations. The animals are then observed for a period of 14 days, during which mortality, clinical signs, and body weight changes are recorded. Post-mortem examinations are conducted to identify any gross pathological changes [28].

2.2.2. Sub-acute toxicity studies:

Sub-acute toxicity studies are designed to investigate the effects of repeated exposure to an herbal remedy over a period of 28 to 90 days [29].

Testing: These studies aim to identify target organs affected by different dosages and to detect potential cumulative effects. They provide a more realistic assessment of toxicity compared to acute studies, as they mimic patterns of human consumption more closely [30].

Dose Selection: Doses for sub-acute studies are typically selected based on information obtained from acute toxicity studies, considering both the LD50 and the slope of the dose-response curve [31].

Study Duration: The duration of sub-acute toxicity studies is determined by the expected duration of human use of the herbal remedy. For products intended for short-term use, 28-day studies may be sufficient, while those for longer-term use may require 90-day studies [32].

Parameters Assessed: Sub-acute toxicity studies evaluate a wide range of parameters, including clinical signs, body weight changes, food and water consumption, hematological and biochemical markers, organ weights, and histopathological changes [33].

2.2.3. Sub-acute toxicity studies:

Chronic toxicity studies investigate the long-term effects of herbal remedies, typically over a period of 6 months to 2 years [34].

Purpose: These studies provide information on potential toxicity from repeated dosing over an extended period, addressing concerns about bioaccumulation in organs and long-term safety [35].

Methodology: Animals are administered the herbal preparation daily at different dose levels, including a dose close to the expected human therapeutic dose. Regular assessments of clinical signs, body weight, food consumption, and periodic blood and urine analyses are conducted [36].

Significance: Chronic toxicity studies are particularly important for herbal remedies intended for long-term or lifelong use, as they can reveal delayed onset toxicities, carcinogenic potential, and effects on reproductive systems that may not be apparent in shorter-term studies [37].

3. Challenges Associated with Regulatory Status for Herbal Medicines

The regulatory landscape for herbal medicines is complex and varies significantly across different countries and regions. This variability poses numerous challenges for manufacturers, healthcare providers, and consumers alike. Some of the key challenges elaborated in Figure 2



Figure 2. Challenges for herbal products

3.1. Historical Context and Current Regulatory Framework

In 1994, the Dietary Supplement Health and Education Act (DSHEA) was passed in the United States, which significantly impacted the regulation of herbal products [39]. Under this act, many herbal preparations were classified as dietary supplements, which did not require pre-market approval or toxicity research. This legislation placed the burden of proof on the Food and Drug Administration (FDA) to demonstrate that a product was unsafe before it could be removed from the market [40]. This regulatory approach contrasts sharply with the framework for conventional pharmaceuticals, where manufacturers must prove safety and efficacy before market approval. The discrepancy has led to several key challenges:

3.2. Key Challenges in Herbal Medicine Regulation

3.2.1. Lack of Standardization

One of the primary challenges in regulating herbal medicines is the lack of standardization in product composition and manufacturing processes [41]. Unlike conventional drugs, herbal products can vary significantly in their chemical composition due to factors such as:

- Differences in plant species and subspecies
- Variations in growing conditions (soil, climate, altitude)
- Harvesting practices and timing
- Processing and extraction methods
- Storage conditions

This variability makes it difficult to ensure consistent quality and safety across different batches or products from different manufacturers [42].

3.2.2. Limited Pre-market Safety Evaluation

The classification of many herbal products as dietary supplements in some countries means they often enter the market without rigorous pre-market safety evaluations [43]. This approach can potentially expose consumers to unknown risks, especially when products contain novel herbal ingredients or combinations.

3.2.3. Inadequate Quality Control

The complex nature of herbal products, often containing hundreds of compounds, makes quality control challenging. Issues such as adulteration, contamination with heavy metals or pesticides, and substitution of plant species are not uncommon [44]. Detecting these problems requires sophisticated analytical techniques that may not be consistently applied across the industry.

3.2.4. Lack of Global Regulatory Harmonization

The regulatory status of herbal medicines varies widely between countries, creating challenges for international trade and consumer safety [45]. For example:

- In the European Union, herbal medicines may be registered as traditional herbal medicinal products if they have a history of traditional use.
- In China, many herbal medicines are regulated as drugs and require extensive safety and efficacy data.
- In the United States, most herbal products are regulated as dietary supplements with minimal pre-market oversight.

This lack of harmonization can lead to confusion among consumers and challenges for manufacturers operating in multiple markets [46].

3.2.5. Limited Post-market Surveillance

The lack of robust pre-market safety evaluations places greater importance on post-market surveillance. However, adverse event reporting for herbal products is often inadequate [47]. Reasons for this include:

- Underreporting by consumers and healthcare providers
- Difficulty in establishing causal relationships due to the complex nature of herbal products
- Lack of standardized reporting systems in many countries

3.2.6. Insufficient Research Funding

Compared to conventional pharmaceuticals, herbal medicines often receive less funding for rigorous scientific research [48]. This lack of investment can result in a dearth of high-quality clinical trials and toxicological studies, making it difficult for regulators to make evidence-based decisions.

3.2.7. Intellectual Property Challenges

Traditional knowledge about herbal medicines often doesn't fit within conventional intellectual property frameworks. This can discourage investment in research and development, as companies may struggle to protect their innovations [49].

3.2.8. Labeling and Claims

Regulations around labeling and health claims for herbal products vary widely. In some jurisdictions, manufacturers are limited in the health claims they can make, while in others, oversight may be less stringent. This inconsistency can lead to consumer confusion and potential misuse of products [50].

3.2.9. Interactions with Conventional Drugs

The potential for herb-drug interactions is a significant concern that is often not adequately addressed by current regulatory frameworks. As herbal product use increases, the risk of adverse interactions with conventional medications also rises, highlighting the need for better integration of herbal medicines into mainstream healthcare systems [51].

3.3. Addressing Regulatory Challenges

To address these challenges, several approaches have been proposed:

- Developing more harmonized global standards for herbal medicine regulation
- Implementing more rigorous quality control measures, including advanced analytical techniques
- Enhancing post-market surveillance systems for herbal products
- Increasing funding for research into the safety and efficacy of herbal medicines
- Improving education for healthcare providers about herbal medicines and their potential interactions
- Developing innovative regulatory approaches that balance traditional use evidence with modern scientific standards [52].

4. Challenges Associated with the Assessment of Safety and Efficacy

For assessing the safety and effectiveness of herbal remedies is far more intricate than those needed for traditional medications. More than hundreds of natural elements can be found in a single herbal medicine or medicinal plant, and several times as many in

a blended herbal medical product. It may be almost hard to identify individual active ingredients in such an examination, particularly if they are in combination. Some key aspects and challenges are shown in Figure 3.

Figure 3. Assessment of Safety and Efficacy

4.1. Complexity of Herbal Preparations

Unlike conventional drugs that typically contain a single active ingredient, herbal medicines often contain hundreds of potentially bioactive compounds [54]. This complexity makes it difficult to identify all active ingredients, determine which compounds are responsible for therapeutic effects, understand potential synergistic or antagonistic interactions between compounds, and establish consistent dosing regimens. Furthermore, the chemical composition of herbal products can vary significantly due to factors such as genetic differences in plant species, environmental conditions during growth, harvesting time and methods, processing and extraction techniques, and storage conditions. This variability can lead to inconsistencies in safety and efficacy profiles between different batches or products from different manufacturers [55].

4.2. Limited Scientific Evidence

Many herbal medicines have a long history of traditional use but lack robust scientific evidence from well-designed clinical trials. Conducting such trials presents numerous challenges, including difficulty in standardizing herbal preparations for study, lack of funding for large-scale trials, ethical considerations in testing traditional medicines, and complexities in designing appropriate placebos for herbal products [56]. While traditional use can provide valuable insights, it may not always align with modern scientific standards for safety and efficacy. Translating traditional concepts of health and disease into modern medical terminology can be challenging, and there may be potential bias in historical accounts of efficacy. Moreover, there is often a lack of systematic documentation of adverse effects in traditional use [57].

4.3. Methodological Challenges in Research

The lack of standardization in herbal products poses significant challenges for research, making it difficult to compare results across different studies, reproduce study findings, and extrapolate results to different herbal preparations [58]. Conventional research methodologies may not always be suitable for evaluating herbal medicines. Designing studies that account for the holistic approach of many traditional medicine systems, developing appropriate outcome measures that capture the multi-faceted effects of herbal medicines, and accounting for individual variability in response to herbal treatments are all significant challenges [59].

4.4. Pharmacokinetic and Pharmacodynamic Complexities

Herbal medicines often work through multiple mechanisms simultaneously, making it challenging to identify all relevant pharmacological actions, understand how different compounds interact within the body, and determine appropriate dosing regimens [60]. The potential for interactions between herbal medicines and conventional drugs is a significant safety concern. Identifying all potential interactions, understanding the mechanisms of these interactions, predicting their clinical significance, and educating healthcare providers and patients about potential risks are ongoing challenges in this field [61].

4.5. Toxicological Considerations

Assessing the long-term safety of herbal medicines is particularly challenging due to the lack of systematic long-term follow-up studies, difficulty in attributing delayed adverse effects to herbal use, and the potential for cumulative toxicity from chronic use [62]. Detecting and characterizing rare adverse events associated with herbal medicines is also challenging due to underreporting of adverse events, difficulty in establishing causality, and the lack of comprehensive post-market surveillance systems [63].

4.6. Quality Control and Adulteration

Ensuring the quality and purity of herbal products is crucial for safety and efficacy assessments. This involves detecting contamination with heavy metals, pesticides, or microorganisms, identifying intentional adulteration with undeclared ingredients, and ensuring correct botanical identification of plant materials [64]. Developing and validating appropriate analytical methods for quality control of herbal products is challenging due to the complex chemical nature of herbal preparations, lack of reference standards for many herbal compounds, and the need for sophisticated and often expensive analytical equipment [65-68].

5. Conclusion

In conclusion, this review has highlighted the complex landscape of herbal medicine safety and regulation. The challenges in toxicity testing, regulatory frameworks, and the assessment of safety and efficacy underscore the need for a multifaceted approach to ensure the responsible use of herbal remedies. While traditional knowledge provides valuable insights, it must be complemented by rigorous scientific evaluation to meet modern standards of safety and efficacy. Moving forward, addressing these challenges will require collaborative efforts from researchers, regulators, manufacturers, and healthcare provider.

References

[1] Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci. 2002;23(3):136-9.

[2] Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116(7):478-85.

[3] Fong HH. Integration of herbal medicine into modern medical practices: issues and prospects. Integr Cancer Ther. 2002;1(3):287-93.

[4] Barnes J. Pharmacovigilance of herbal medicines. Drug Saf. 2003;26(12):829-51.

[5] Tummala SR, Gorrepati N. AI-driven Predictive Analytics for Drug Stability Studies. Journal of Pharma Insights and Research. 2024 Apr 25;2(2):188-98

[6] Efferth T, Kaina B. Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Curr Drug Metab. 2011;12(10):989-96.

[7] Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med. 2002;252(2):107-13.

[8] Fürst R, Zündorf I. Evidence-based phytotherapy in Europe: where do we stand? Planta Med. 2015;81(12-13):962-7.

[9] Wiesner J, Knöss W. Future visions for traditional and herbal medicinal products—a global practice for evaluation and regulation? J Ethnopharmacol. 2014;158:516-8.

[10] Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ. Buyer beware? Does the information provided with herbal products available over the counter enable safe use? BMC Med. 2011;9:94.

[11] Sahoo N, Manchikanti P, Dey S. Herbal drugs: standards and regulation. Fitoterapia. 2010;81(6):462-71.

[12] Chan K. Some aspects of toxic contaminants in herbal medicines. Chemosphere. 2003;52(9):1361-71.

[13] Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104(2):170-8.

[14] Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res. 2000;33(2):179-89.

[15] Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513-8.

[16] Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm. 2000;57(10):963-9.

[17] Ernst E. Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol. 2000;56(8):523-4.

[18] De Smet PA. Herbal remedies. N Engl J Med. 2002;347(25):2046-56.

[19] Cuzzolin L, Zaffani S, Benoni G. Safety implications regarding use of phytomedicines. Eur J Clin Pharmacol. 2006;62(1):37-42.

[20] Marcus DM, Grollman AP. Botanical medicines--the need for new regulations. N Engl J Med. 2002;347(25):2073-6.

[21] Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401-9.

[22] Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134-49.

[23] Ernst E. Challenges for phytopharmacovigilance. Postgrad Med J. 2004;80(943):249-50.

[24] Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med. 2003;163(6):699-704.

[25] Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387-91.

[26] Ernst E. Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf. 2004;13(11):767-71.

[27] Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280(18):1569-75.

[28] Rao TS, Tirumala R, Rao PS. Quantification of tamsulosin in human plasma using LC-MS/MS. Journal of Bioanalysis & Biomedicine. 2011 Mar 3;3

[29] Kessler RC, Davis RB, Foster DF, Van Rompay MI, Walters EE, Wilkey SA, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med. 2001;135(4):262-8.

[30] Mangam VT, Nallam VR, Anitha A, Devi PR, Sanisha M. Dengue-An Overview. International Journal of Pharma Research. 2018 Jan 1;9(1).

[31] Linde K, Willich SN. How objective are systematic reviews? Differences between reviews on complementary medicine. J R Soc Med. 2003;96(1):17-22.

[32] Ernst E. The efficacy of herbal medicine--an overview. Fundam Clin Pharmacol. 2005;19(4):405-9.

[33] Ernst E, Pittler MH. Herbal medicine. Med Clin North Am. 2002;86(1):149-61.

[34] Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134-8

[35] Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777-98.

[36] Gorrepati N, Tummala SR. A Case Report on Antiphospholipid Antibody Syndrome with Chronic Pulmonary Embolism Secondary to Deep Vein Thrombosis and Thrombocytopenia: Case report. Journal of Pharma Insights and Research. 2024 Apr 30;2(2):272-4

[37] Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf. 2003;26(15):1075-92.

[38] Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit. 2005;27(5):549-57.

[39] Boullata JI, Nace AM. Safety issues with herbal medicine. Pharmacotherapy. 2000;20(3):257-69.

[40] Rousseaux CG, Schachter H. Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Birth Defects Res B Dev Reprod Toxicol. 2003;68(6):505-10.

[41] Ernst E. Herbal medicines: balancing benefits and risks. Novartis Found Symp. 2007;282:154-67.

[42] Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144(5):364-7.

[43] Heinrich M, Barnes J, Gibbons S, Williamson EM. Fundamentals of pharmacognosy and phytotherapy. 2nd ed. Edinburgh: Churchill Livingstone; 2012.

[44] Kumar SP, Kanthal LK, Durga S, Satyavati K. Phytochemical Evaluation and Screening of Cardiotonic, Antibacterial and Anthelmintic Activities of Sida cordifolia L. Int J Pharm Sci Nanotechnol. 2014 Aug 31;7(3):2567-73.

[45] Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. Evid Based Complement Alternat Med. 2007;4(Suppl 1):37-40.

[46] Cordell GA. Phytochemistry and traditional medicine - A revolution in process. Phytochem Lett. 2011;4(4):391-8.

[47] Sarella PN, Thammana PK. Potential applications of Folate-conjugated Chitosan Nanoparticles for Targeted delivery of Anticancer drugs. Research Journal of Pharmaceutical Dosage Forms and Technology. 2023 Oct 1;15(4):281-8.

[48] Ernst E. Herbal medicines: where is the evidence? BMJ. 2000;321(7258):395-6.

[49] Sarris J, Ng CH, Schweitzer I. 'Omic' genetic technologies for herbal medicines in psychiatry. Phytother Res. 2012;26(4):522-7

[50] Sarella PN, Mangam VT. AI-Driven Natural Language Processing in Healthcare: Transforming Patient-Provider Communication. Indian Journal of Pharmacy Practice. 2024;17(1).

[51] Liang YZ, Xie P, Chan K. Quality control of herbal medicines. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;812(1-2):53-70.

[52] Xue CC, Zhang AL, Lin V, Da Costa C, Story DF. Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med. 2007;13(6):643-50.

[53] Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854-9.

[54] Rates SM. Plants as source of drugs. Toxicon. 2001;39(5):603-13.

[55] Verpoorte R, Choi YH, Kim HK. Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol. 2005;100(1-2):53-6.

[56] Jütte R, Heinrich M, Helmstädter A, Langhorst J, Meng G, Niebling W, et al. Herbal and naturopathic medicine: definitions, regulatory status and scientific approaches. Forsch Komplementmed. 2017;24(2):88-93.

[57] Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001;109(Suppl 1):69-75.

[58] Vlietinck A, Pieters L, Apers S. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European Union. Planta Med. 2009;75(7):683-8.

[59] Vickers A, Zollman C, Lee R. Herbal medicine. West J Med. 2001;175(2):125-8.

[60] Raskin I, Ribnicky DM, Komarnytsky S, Ilic N, Poulev A, Borisjuk N, et al. Plants and human health in the twenty-first century. Trends Biotechnol. 2002;20(12):522-31.

[61] Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001;52(5):587-95.

[62] Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70(9):1731-8.

[63] Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol. 2000;143(5):923-9.

[64] Jiang Y, David B, Tu P, Barbin Y. Recent analytical approaches in quality control of traditional Chinese medicines—a review. Anal Chim Acta. 2010;657(1):9-18.

[65] Sahoo N, Manchikanti P. Herbal drug regulation and commercialization: an Indian industry perspective. J Altern Complement Med. 2013;19(12):957-63.

[66] Fan TP, Deal G, Koo HL, Rees D, Sun H, Chen S, et al. Future development of global regulations of Chinese herbal products. J Ethnopharmacol. 2012;140(3):568-86.

[67] Bodeker G, Ong CK, Grundy C, Burford G, Shein K. WHO global atlas of traditional, complementary and alternative medicine. Kobe, Japan: World Health Organization, Centre for Health Development; 2005.

[68] Singh D, Gupta R, Saraf SA. Herbs-are they safe enough? An overview. Crit Rev Food Sci Nutr. 2012;52(10):876-98.

Author's short biography

Dr Neeta Rai

Dr. Neeta Rai has more than 11 years of academic experience. She has completed her PhD from SSSUTMS, Sehore (M.P). She has Indian patents, books, and book chapters on her accolades. She had received many best poster awards at several international and national conferences. She is also a recipient of the Young Researcher Award by IAEP in 2022 and the Best Researcher Award at in international conference in 2023. Her H Index is 4 and she has published research and review publications in reputed journals having good impact factors

Dr Amrita Thakur

Dr. Amrita Thakur has more than 10 years of academic experience. She has books, and book chapters on her accolades. She had received many best poster awards at several international and national conferences. Her interest area is Hydrogels, polymers, solubilization technique, hydrotrophy, enzyme immobilization. Her H Index is 5 and she has published research and review publications in reputed journals having good impact factors

Miss Vaishnavi Shreepathi

Completed Bachelor of Pharmacy from Vishwakarma University, Pune. She is interested in drug regulatory affairs, research focuses on novel drug delivery systems and pharmaceuticals. They aim to innovate and enhance pharmaceutical formulations through diligent research

Mr Siddharth Chavan

Siddharth Chavan completed Bachelor of Pharmacy from Vishwakarma University, Pune. He is interested in drug regulatory affairs, pharmacovigilance with research focusing on advanced drug delivery systems and pharmaceutical innovations. Siddharth aims to enhance therapeutic outcomes through diligent research